Originally posted here:
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
Related Post
- Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update - April 4th, 2025
- Praxis Precision Medicines to Participate in Upcoming April Conferences - April 4th, 2025
- Anne Whitaker Appointed as Non-Executive Director - April 4th, 2025
- Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)... - April 4th, 2025
- Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025 - April 4th, 2025
- Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs - April 4th, 2025
- Dogecoin Cash, Inc. Subsidiary PrestoDoctor Launches April Promotion Offering 42.0% Off Medical Cannabis Evaluations - April 4th, 2025
- New LabTAG Add-On Streamlines Laboratory Labeling with Dymo® LabelWriter™ 5-Series and eLabNext Integration - April 4th, 2025
- Verano to Report First Quarter 2025 Financial Results on May 8, 2025 - April 4th, 2025
- AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States - April 4th, 2025
- NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - April 4th, 2025
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2025
- Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral... - April 4th, 2025
- Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - April 4th, 2025
- Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease - April 4th, 2025
- NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement - April 4th, 2025
- Better Choice Company Signs Definitive Agreement for SRx Health Solutions to Convert CAD$4 Million in Debt to Equity - April 4th, 2025
- Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider - April 4th, 2025
- Renovaro Provides Update to Definitive Agreement with Predictive Oncology - April 4th, 2025
- Better Choice Company Chairman Provides Shareholder Update on SRx Health Acquisition and Comments on Recent Debt-to-Equity Transaction - April 4th, 2025
- Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - April 1st, 2025
- Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia - April 1st, 2025
- Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - April 1st, 2025
- Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological... - April 1st, 2025
- Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - April 1st, 2025
- Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - April 1st, 2025
- Revolution Medicines to Participate in April 2025 Investor Conferences - April 1st, 2025
- Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled... - April 1st, 2025
- Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - April 1st, 2025
- Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - April 1st, 2025
- Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - April 1st, 2025
- Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - April 1st, 2025
- Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - April 1st, 2025
- Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update - April 1st, 2025
- Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - April 1st, 2025
- ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - April 1st, 2025
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - April 1st, 2025
- Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 - April 1st, 2025
- Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine - April 1st, 2025
- Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order - April 1st, 2025
- Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 - March 30th, 2025
- Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman - March 30th, 2025
- Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of... - March 30th, 2025
- Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show - March 30th, 2025
- Aptose Reports Year End 2024 Results and Corporate Highlights - March 30th, 2025
- Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - March 30th, 2025
- Strategic update on the progress and development of Molecure's key clinical projects in 2024 - March 30th, 2025
- FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate... - March 30th, 2025
- NTG Nordic Transport Group A/S – Annual General Meeting 2025 - March 30th, 2025
- Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - March 30th, 2025
- HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - March 30th, 2025
- Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - March 30th, 2025
- Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 30th, 2025
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - March 30th, 2025
- Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - March 30th, 2025
- Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates - March 30th, 2025
- Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery... - March 30th, 2025
- Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension... - March 30th, 2025
- Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 - March 30th, 2025
- Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - March 28th, 2025
- Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - March 28th, 2025
- AEON Biopharma Announces CEO Transition - March 28th, 2025
- Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - March 28th, 2025
- Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - March 28th, 2025
- BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - March 28th, 2025
- Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug... - March 28th, 2025
- CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update - March 28th, 2025
- Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025 - March 28th, 2025
- INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - March 28th, 2025
- Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - March 28th, 2025
- Tempest Reports Year End 2024 Financial Results and Provides Business Update - March 28th, 2025
- Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients... - March 28th, 2025
- Teva Releases Q1 2025 Aide Memoire - March 28th, 2025
- Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 - March 28th, 2025
- Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025 - March 28th, 2025
- Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results - March 28th, 2025
- Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - March 28th, 2025
- DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License... - March 28th, 2025
- Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results - March 28th, 2025
- Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025 - March 25th, 2025
Recent Comments